Back to top
more

PDL BioPharma (PDLI)

(Delayed Data from NSDQ)

$2.47 USD

2.47
NA

0.00 (0.00%)

Updated Dec 30, 2020 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2%

PDL BioPharma, Inc. (PDLI) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.

    AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate

    AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.

      Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss

      Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q3. However, shares were down in after-hours trading.

        PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y

        PDL BioPharma's (PDLI) earnings top estimates in Q3. Revenues also grow year over owing to rise in royalty rights.

          Amgen Label Expansion Application for Prolia Accepted by FDA

          Amgen (AMGN) announced that the FDA has accepted its regulatory application in the U.S. seeking label expansion for Prolia for treating patients with glucocorticoid-induced osteoporosis (GIOP).

            Seattle Genetics (SGEN) in Focus: Stock Moves 7.9% Higher

            Seattle Genetics (SGEN) was a big mover last session, as the company saw its shares rise nearly 8% on the day amid huge volumes.

              ProQR's Genetic Disorder Candidate Gets Orphan Drug Status

              ProQR Therapeutics (PRQR) announced that its investigational dystrophic epidermolysis bullosa candidate, QR-313, was granted orphan drug designation by the FDA.

                Should Value Investors Consider PDL BioPharma, Inc. (PDLI) Stock?

                PDL BioPharma is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

                  Pluristem's Ischemia Candidate Gets Fast Track Designation

                  Pluristem Therapeutics' (PSTI) phase III study of PLX-PAD cells in patients with critical limb ischemia granted Fast Track designation by the FDA.

                    3 Pharma/Biotech Sector Bargains for a Healthy Portfolio

                    The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.

                      Why PDL BioPharma (PDLI) Could Be Positioned for a Surge

                      PDL BioPharma, Inc. (PDLI) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.

                        Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix Medical and Intrepid Potash

                        Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix Medical and Intrepid Potash

                          Swarup Gupta headshot

                          5 Bargain Breakout Stocks Offering Stunning Returns

                          The key to this kind of stock selection is to identify players that are trading within a narrow band.

                            Top Ranked Momentum Stocks to Buy for August 24th

                            Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 24th:

                              Top Ranked Momentum Stocks to Buy for August 23rd

                              Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 23rd:

                                3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock

                                PDL BioPharma (PDLI) stock is looking quite impressive now for momentum-oriented investors.

                                  Top Ranked Momentum Stocks to Buy for August 16th

                                  Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 16th:

                                    PDL BioPharma (PDLI) Q2 Earnings Beat, Revenues Rise Y/Y

                                    PDL BioPharma's (PDLI) earnings surpass expectations. Revenues also significantly increase year over year, thanks to a rise in fair value of the Depomed royalty asset.

                                      PDL BioPharma (PDLI) Up 5.9% Since Earnings Report: Can It Continue?

                                      PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        Can PDL BioPharma Be a Top Choice for Value Investors?

                                        Value Investors might consider PDL BioPharma (PDLI) as a great pick on the back of its key value statistics.